Lucid Diagnostics Inc.
corporate_fare Company Profile
Lucid Diagnostics Inc. (NASDAQ:LUCD) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for LUCD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for LUCD spans 10-Q, 8-K, DEF 14A, PRE 14A.
Recent high-impact activity:
- Lucid 10-Q: Going Concern Reaffirmed as Cash Falls to $18.0M and Note Conversion Price Resets to $0.3519
- Lucid Posts $1.2M Q3 Revenue as Medicare Starts Paying for EsoGuard
- Medicare Now Paying for EsoGuard; Q3 Revenue $1.2M, Record October Volume
- Lucid Diagnostics Starts Collecting Medicare Payment for EsoGuard, Closes $15M Preferred Financing
- Lucid Diagnostics Raises $15M in Series C Preferred Priced at $0.3519 Conversion
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 14,987,206 shares in LUCD as of the October 30, 2026 settlement, a 10.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 64.0% of LUCD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.